Last week, President Trump unveiled his administration’s Artificial Intelligence (AI) Action Plan for America, a sweeping, 90‑point policy initiative aimed at securing U.S. dominance in AI through deregulation efforts, infrastructure investment, and global export strategy.
At the same time, the president also signed three executive orders to support the Action Plan and promote U.S. leadership in AI. These include:
- An “Unbiased AI Principles” order barring federal procurement of AI systems with ideological bias and requiring “truth-seeking” and ideological neutrality in LLMs, or Large Language Models;
- An AI Data Center Infrastructure order to accelerate permitting and offering financial incentives for qualifying high-value projects with large computing capacity; and
- An AI Export order promoting adoption of American AI technology and AI exports to U.S. allies, including construction of data centers and other infrastructure in target countries.
As the use of AI continues to grow rapidly and its integration into the various sectors of the healthcare industry expands, let’s briefly review some initial thoughts around the AI Action Plan’s healthcare implications, which stem from the three pillars the Plan is built upon. These are:
- Accelerating innovation by directing federal agencies to strip away “unnecessary red tape” that hinders AI development;
- Building infrastructure, with a central feature of fast-tracking environmental permitting for data centers and energy infrastructure, including access to federal land for development; and
- Emphasizing global leadership, specifying that the U.S. will export AI technology packages to allies, thereby asserting American governance models and standards globally.
Interestingly, the Action Plan directs agencies like the Food and Drug Administration (FDA) to establish regulatory “sandboxes” or “AI Centers of Excellence.” These frameworks are designed to fast-track testing and deployment of AI tools in healthcare, enabling safer and quicker uptake in areas such as diagnostics, predictive analytics, and drug development.
The Plan also suggests thatbuilding a massive, modernized AI infrastructure should deliver the computing power needed for advanced healthcare AI. Initiatives like “Stargate,” a $500 billion venture launched by the president with several tech giants, are expected to add significant infrastructure capacity and job growth, with potential applications in early cancer detection and therapeutic development.
Elsewhere, the Action Plan references workforce retraining to support AI adoption. Health systems and other provider groups dealing with staffing shortages may benefit from AI-assisted workflows – but, as some analysts have argued, only if clinicians are equipped, and governance structures are in place to oversee AI-driven decisions. In this way, the Action Plan presents new opportunities to align value-based care designs with the use of AI for things like improving operational efficiencies.
Now, some observers warn that while the plan lays an ambitious foundation, it is vague on critical areas such as resolving intellectual property and copyright issues in training AI data models.
And although the Action Plan promotes rapid AI adoption and infrastructure opportunities, critics warn that deregulation may weaken safeguards under the Health Insurance Portability and Accountability Act (HIPAA) and reduce oversight of things like bias and transparency in AI systems, which could compromise public trust in such systems when deployed in patient care.
One particular health AI innovator further cautions that these systems must be internally governed with strong ethical frameworks, especially in patient‑facing applications.
President Trump’s AI Action Plan marks a major pivot toward furthering his deregulatory agenda and advancing American leadership internationally in AI. In healthcare, it offers a potential leap forward in a variety of areas. Yet the plan leaves open critical questions on ethics, data-privacy, and sustainability.
As the healthcare industry evaluates AI adoption, both providers and regulators will, now more than ever, have to balance the promise of technological transformation with rigorous governance and strong patient protections. Stay tuned, because these are still only the beginning stages of refining government regulation in healthcare AI.
Reference material
- The White House
- TIME
- Inside Privacy
- Global Policy Watch
- The Verge
- Lumeris
- BHM Healthcare Solutions
- Here
- Here
- Here